pharmacy

Top 3 strategies employers should use to decrease healthcare costsA new Willis Towers Watson survey finds that U.S. employers have three key strategies to building cost-effective healthcare programs. 
When Going the Extra Mile isn’t Enough
When Going the Extra Mile isn’t EnoughWhat do you do about the customer who is never satisfied?
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Expedited FDA approval plays dominant role in drug approvalsLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Creating a ‘robust’ specialty pharmacy networkThe correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.
FDA approvals for specialty drugs to pick up in 2017Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
Health policy changes could affect reimbursement: What to knowHere’s what a Vizient’s hospital leader survey says about the future of the Affordable Care Act (ACA) and other healthcare policies under the new Administration.
Poll: Few consumers trust health orgs, pharmaA new report has troubling findings for payers, providers, and technology companies. Here are the key takeaways, and reactions from experts.